Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02028689 · ClinicalTrials.gov registry record · Phase 1

Metformin and Furosemide Drug-Drug Interaction Study

A Phase 1 study, sponsored by Ardea Biosciences.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target

NCT02028689: Completed Phase 1 study, sponsored by Ardea Biosciences.

NCT02028689 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02028689, a Phase 1 study, has completed, sponsored by Ardea Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target

Study Summary

This study will assess the potential effects of lesinurad on the pharmacokinetics (PK) of metformin and furosemide in healthy, adult male subjects.

Primary Outcome

Profile in terms of maximum observed concentration (Cmax), time of occurence of maximum observed concentration (Tmax), area under the concentration-time curve (AUC), and apparent terminal half-life (t1/2).

Interventions

  • DRUG Furosemide 40 mg
  • DRUG Lesinurad 400 mg
  • DRUG Metformin 850 mg

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2013-10
Est. Completion 2014-01
Phase Phase 1
Ardea Biosciences

32 total trials

What the finished NCT02028689 record still lists

NCT02028689 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 3 interventions - of which Furosemide 40 mg is the first listed.

NCT02028689 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02028689 about?

NCT02028689 is a clinical study titled "Metformin and Furosemide Drug-Drug Interaction Study". This study will assess the potential effects of lesinurad on the pharmacokinetics (PK) of metformin and furosemide in healthy, adult male subjects.

What is the current status of trial NCT02028689?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-10. Estimated completion is 2014-01.

What interventions are being tested in trial NCT02028689?

The interventions under investigation include: Furosemide 40 mg (DRUG), Lesinurad 400 mg (DRUG), Metformin 850 mg (DRUG).

Who is sponsoring clinical trial NCT02028689?

This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02028689's enrollment target sits among peer trials

23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02028689, the US trial registry maintained by the National Library of Medicine. NCT02028689 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.